Margaret McCormick, PhD, Named Executive Director of Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI) has named Margaret McCormick, PhD, as its executive director/chief operating officer and Virginia Mason Medical Center vice president of Research.
Dr. McCormick previously served as BRI’s chief administrative officer, with direct oversight of operational functions including human resources, finance, facilities and safety.
“In her fourteen months with BRI, Dr. McCormick has already made significant contributions and been instrumental in the development of our five-year strategic plan,” said Jane Buckner, MD, president of BRI. “Her background as a scientist and achievements in life science industry are tremendous assets as she moves into this key leadership role for our organization,” Dr. Buckner said.
McCormick holds a PhD in biology from the Massachusetts Institute of Technology and a Bachelor’s of Science from the University of Wisconsin – Madison. Before coming to BRI, she served as CEO of Matrix Genetics, an industrial biotechnology company in Seattle; as a principal at life sciences investment firm Integra Ventures; and as a consultant for McKinsey & Company. She also serves on the Life Science Washington Board of Directors.
Her predecessor in the role of BRI Executive Director/COO, Homer W. Lane Jr., retired effective March 1.
About Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI) is a world-renowned, non-profit research institute committed to advancing the science that will predict, prevent, reverse and cure diseases of the immune system. BRI researchers uniquely study the immune system in both health and disease, with the ultimate goal of achieving a healthy immune system for each individual. Diseases we study include type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis, Crohn’s and colitis as well as allergies and cancer. BRI accelerates discovery through laboratory breakthroughs in immunology that can be translated to clinical therapies. A leader of collaborative initiatives such as the Immune Tolerance Network and Type 1 Diabetes TrialNet, BRI frequently partners with global research institutes, pharmaceutical and biotech companies.
Christi B. Nichols
Marketing Communications & External Relations
email@example.com / 206-342-6519